Recurrent Breast Cancer Treated Successfully with Mitomycin-C and Vinblastine after Failure of Both Doxorubicin-containing Regimen and Paclitaxel-A Case Report.
スポンサーリンク
概要
- 論文の詳細を見る
Cross-resistance is one of the chief obstacles in salvage therapy for refractory breast cancer. Although paclitaxel is one of the most promising drugs, it shows a response rate of 30% at most for patients with breast cancer resistant to doxorubicin, and no effective treatments for tumors refractory to both agents have been reported. We describe a 38-year-old woman with recurrent breast cancer, who was treated successfully with mitomycin-C and vinblastine after doxorubicin-based chemotherapy and paclitaxel failed. The combinations of mitomycin-C and microtubule inhibitors including vinca alkaloids and taxanes may have a potential application to refractory breast cancer.
- 東北ジャーナル刊行会の論文
東北ジャーナル刊行会 | 論文
- Effects of Ketamine and Propofol on the Ratio of Interleukin-6 to Interleukin-10 during Endotoxemia in Rats
- α2-Adrenergic Modulation of Glucagon and Insulin Secretions in Sheep
- Molecular Analysis of the Pathogenesis of Autoimmune Insulitis in NOD Mice
- Effects of Thymoxamine in Ouabain-Induced Arrhythmias in Dogs
- T Cell Hypofunctions and Glomerular Sclerotic and Angiogenic Changes Found Both in Rats Received Unilateral Nephrectomy plus Transplantation of Syngeneic Mesenteric Lymph Nodes and in Rats Received Unilateral Nephrectomy plus Splenectomy